Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development
Illumina (NASDAQ:ILMN) has launched Illumina Protein Prep, a groundbreaking NGS-based proteomics assay capable of measuring 9,500 unique human protein targets. This launch follows the company's agreement to acquire SomaLogic, strengthening its position in the proteomics market.
The technology has demonstrated significant impact through early access programs, with 30,000 samples processed using the 6K assay and over 6,000 samples with the 9.5K assay. Notable success includes Genomics England's implementation in their 100,000 Genomes Project, which achieved a 7.5% increase in diagnostic yield for rare diseases.
The solution combines Illumina NovaSeq sequencing platforms with DRAGEN Protein Quantification and Connected Multiomics software, enabling researchers to streamline analysis from discovery to therapeutic development. The company has also announced a pilot program with UK Biobank to analyze 50,000 samples using this technology.
Illumina (NASDAQ:ILMN) ha lanciato Illumina Protein Prep, un innovativo test proteomico basato su NGS in grado di misurare 9.500 target proteici umani unici. Questo lancio segue l'accordo per l'acquisizione di SomaLogic, che rafforza la posizione dell'azienda nel mercato della proteomica.
La tecnologia ha dimostrato un impatto significativo nei programmi di accesso anticipato, con 30.000 campioni processati con il saggio 6K e oltre 6.000 campioni con il saggio 9.5K. Un successo rilevante è l'adozione da parte di Genomics England nel loro 100.000 Genomes Project, che ha ottenuto un incremento del 7,5% nella resa diagnostica per le malattie rare.
La soluzione combina le piattaforme di sequenziamento Illumina NovaSeq con DRAGEN Protein Quantification e il software Connected Multiomics, permettendo ai ricercatori di semplificare l'analisi dalla scoperta allo sviluppo terapeutico. L'azienda ha inoltre annunciato un programma pilota con UK Biobank per analizzare 50.000 campioni con questa tecnologia.
Illumina (NASDAQ:ILMN) ha lanzado Illumina Protein Prep, un innovador ensayo proteómico basado en NGS capaz de medir 9.500 objetivos proteicos humanos únicos. Este lanzamiento se produce tras el acuerdo de la compañía para adquirir SomaLogic, reforzando su posición en el mercado de la proteómica.
La tecnología ha mostrado un impacto significativo en programas de acceso anticipado, con 30.000 muestras procesadas con el ensayo 6K y más de 6.000 muestras con el ensayo 9.5K. Un éxito destacado es la implementación por parte de Genomics England en su 100.000 Genomes Project, que logró un aumento del 7,5% en el rendimiento diagnóstico para enfermedades raras.
La solución combina las plataformas de secuenciación Illumina NovaSeq con DRAGEN Protein Quantification y el software Connected Multiomics, permitiendo a los investigadores agilizar el análisis desde el descubrimiento hasta el desarrollo terapéutico. La compañía también ha anunciado un programa piloto con UK Biobank para analizar 50.000 muestras con esta tecnología.
Illumina (NASDAQ:ILMN)는 NGS 기반의 획기적인 단백질체 검사인 Illumina Protein Prep를 출시했으며, 9,500개의 고유한 인간 단백질 표적을 측정할 수 있습니다. 이번 출시는 SomaLogic 인수 합의에 따른 것으로, 단백질체 시장에서의 입지를 강화합니다.
이 기술은 초기 접근 프로그램을 통해 상당한 효과를 입증했으며, 6K 검사로 30,000건의 샘플을 처리했고 9.5K 검사로는 6,000건 이상을 처리했습니다. 주목할 만한 성과로는 Genomics England가 100,000 Genomes Project에 도입하여 희귀질환의 진단 성과를 7.5% 증가시킨 사례가 있습니다.
해당 솔루션은 Illumina NovaSeq 시퀀싱 플랫폼을 DRAGEN Protein Quantification 및 Connected Multiomics 소프트웨어와 결합하여 연구자들이 발견 단계에서 치료제 개발까지 분석을 간소화할 수 있게 합니다. 또한 회사는 이 기술을 사용해 50,000개 샘플을 분석하는 UK Biobank 파일럿 프로그램을 발표했습니다.
Illumina (NASDAQ:ILMN) a lancé Illumina Protein Prep, un test de protéomique innovant basé sur le NGS capable de mesurer 9 500 cibles protéiques humaines uniques. Ce lancement fait suite à l'accord de rachat de SomaLogic, renforçant la position de l'entreprise sur le marché de la protéomique.
La technologie a démontré un impact significatif lors de programmes d'accès anticipé, avec 30 000 échantillons traités avec le test 6K et plus de 6 000 échantillons avec le test 9,5K. Parmi les réussites notables figure l'adoption par Genomics England dans le cadre de son 100 000 Genomes Project, qui a permis une augmentation de 7,5% du rendement diagnostique pour les maladies rares.
La solution combine les plateformes de séquençage Illumina NovaSeq avec DRAGEN Protein Quantification et le logiciel Connected Multiomics, permettant aux chercheurs de rationaliser l'analyse de la découverte au développement thérapeutique. L'entreprise a également annoncé un programme pilote avec UK Biobank pour analyser 50 000 échantillons avec cette technologie.
Illumina (NASDAQ:ILMN) hat Illumina Protein Prep auf den Markt gebracht, einen bahnbrechenden, NGS-basierten Proteomik-Assay, der 9.500 einzigartige menschliche Proteinziele messen kann. Dieser Start folgt der Vereinbarung des Unternehmens zur Übernahme von SomaLogic und stärkt damit seine Position im Proteomikmarkt.
Die Technologie hat in Early-Access-Programmen deutliche Wirkung gezeigt: 30.000 Proben wurden mit dem 6K-Assay und mehr als 6.000 Proben mit dem 9,5K-Assay verarbeitet. Erwähnenswerter Erfolg ist die Implementierung durch Genomics England im 100.000 Genomes Project, die eine 7,5%ige Steigerung der diagnostischen Ausbeute bei seltenen Krankheiten erzielte.
Die Lösung kombiniert Illumina NovaSeq-Sequenzierplattformen mit DRAGEN Protein Quantification und der Connected Multiomics-Software, wodurch Forscher die Analyse vom Entdeckungsstadium bis zur Wirkstoffentwicklung straffen können. Das Unternehmen kündigte zudem ein Pilotprogramm mit UK Biobank an, um 50.000 Proben mit dieser Technologie zu analysieren.
- Launch of comprehensive proteomics solution measuring 9,500 unique human protein targets - the highest with NGS readout
- Early success with 7.5% increase in diagnostic yield for rare diseases in Genomics England's program
- Strategic acquisition of SomaLogic strengthens market position in proteomics
- Significant market validation with 36,000+ samples processed during early access program
- Major partnership with UK Biobank for 50,000-sample analysis program
- Regulatory clearances still pending for SomaLogic acquisition
- Reliance on third-party suppliers for critical components
- Manufacturing scalability challenges for new instrumentation and consumables
Insights
Illumina's Protein Prep launch significantly expands its proteomics capabilities, strengthening its multiomics strategy and pharmaceutical research positioning.
Illumina's launch of Protein Prep represents a significant advancement in next-generation sequencing (NGS) based proteomics. The ability to measure 9500 unique human protein targets places this technology at the forefront of the field, offering unprecedented scale for proteomics discovery. This capability is particularly valuable for pharmaceutical research, as it enables researchers to simultaneously interrogate thousands of proteins in a single experiment.
The technology's technical advantages are substantial. By leveraging SOMAmer™ technology with Illumina's NovaSeq™ sequencing platforms and DRAGEN™ analysis software, Illumina has created an integrated workflow from sample to insights. Early access results showing 30,000 samples processed with the 6K assay and 6,000 samples with the 9.5K assay demonstrate robust validation and adoption.
Real-world application evidence is compelling. Genomics England's use of Protein Prep in their 100,000 Genomes Project has already yielded a 7.5% increase in diagnostic yield for rare diseases—a significant improvement over their previous 25% diagnostic rate. Similarly, researchers at the University of Colorado are using this technology to investigate why immunotherapies are less effective against rare melanomas, potentially leading to new diagnostic and therapeutic approaches.
Strategically, this launch aligns with Illumina's pending acquisition of SomaLogic, signaling a deliberate expansion into the proteomics market. The integration of proteomics with Illumina's genomics capabilities positions the company as a more comprehensive player in the multiomics field—an increasingly important approach for understanding complex biological systems and developing precision therapies. This unified approach could accelerate biomarker discovery and therapeutic development across multiple disease areas, particularly in cancer and rare diseases where genetic information alone has provided incomplete insights.
Illumina Protein Prep can measure 9500 unique human protein targets, offering new insights into protein biology to fuel novel discovery for treatment of disease
Following early access program, customers commend scale, high consistency, and easy sample to insights workflow
Launch follows Illumina's announcement of agreement to acquire SomaLogic
"NGS-based proteomics provides critical speed, accuracy, reproducibility, and scalability to power large studies and accelerate the drug discovery pipeline for our ecosystem partners in biopharma," said Steve Barnard, chief technology officer of Illumina. "Proteomics is essential to advancing our understanding of disease and is a central pillar of multiomics. Illumina Protein Prep will help deliver multiomics at scale to transform biologic discovery."
Proteomics offers a view into proteins and their functions in biologic processes. Understanding their roles in gene expression and how proteins change throughout disease states is critical to biomarker discovery and precision therapy development. Illumina Protein Prep is powered by SOMAmer™ technology and can measure 9500 unique human protein targets, the most with an NGS readout; offering the greatest insights into protein biology.
Combining Illumina Protein Prep with the power and scalability of Illumina NovaSeq™ sequencing platforms enables the simultaneous interrogation of thousands of proteins in a single experiment, maximizing the discovery power of proteomics studies. After sequencing, Illumina DRAGEN™ Protein Quantification and Connected Multiomics software work together to turn complex proteomic data into clear insights. This powerful combination helps researchers streamline analysis and accelerate progress from discovery to therapeutic development, supporting pharma, contract research organizations, and translational research worldwide.
Early access customers commend scale, high consistency, and easy workflow
Since 2024, Illumina has worked with nearly 40 early collaborators to pilot Illumina Protein Prep, informing development and leading to an optimized customer experience. Since the inception of early access, about 30,000 samples have been processed with the Illumina Protein Prep 6K assay and over 6000 samples with the Illumina Protein Prep 9.5K assay, which was made available through early access this March.
Illumina Protein Prep accelerates global discovery initiative in rare disease
Proteomic studies bridge the gap between genotype and phenotype, providing a real-time snapshot of cellular activity between healthy and disease states. Large-scale proteomic studies can accelerate the discovery of biomarkers for the early detection and monitoring of cancer and other diseases. Proteogenomics studies, which combine proteomic, genomic, and transcriptomic data, identify critical links between gene variants and protein expression that can be used to guide drug discovery.
Researchers leading Genomics England's 100,000 Genomes Project have implemented a multiomics program aimed at improving upon the 2019 diagnostic yield of about
"Until now, proteomics has been considered as a standalone research test, and what this study shows is it will have a much bigger clinical impact on both rare and common diseases," said Professor Matthew Brown, chief scientific officer of Genomics England. "I am confident based on our pilot that proteomics will have significant clinical value in the not-too-distant future."
The findings stemmed from the discovery of abundant differential proteins in specific disease categories, which supports the diagnostic potential of proteomics to advance rare genetic disease research by revealing disease-associated genes and pathways.
"The large content and high analytical sensitivity of Illumina Protein Prep is a big advantage to identify the differentially abundant proteins that link strongly with known factors involved in the disease category concerned, especially with rare disease," said Brown.
Leveraging proteomics to understand rare melanomas
Immunotherapy has changed how oncologists treat cutaneous melanomas—a common and aggressive form of skin cancer. Unfortunately, these therapies are less effective against rare melanomas, such as ocular, acral, and mucosal. Kasey Couts, PhD, codirector of the CU Center for Rare Melanomas at the University of Colorado Anschutz Medical Campus, is working to understand why this happens and investigating new ways to improve melanoma care.
Illumina Protein Prep is giving Couts's research team a powerful, unbiased tool to interrogate these unique conditions. Other proteomic technologies the lab has used were limited to 92 proteins.
"Illumina Protein Prep can help us identify as many as 9500 proteins," Couts said. "This scale is tremendously useful, as we try to dissect the mechanisms that are making these rare tumors resistant to immunotherapy."
The team is using Illumina Protein Prep to investigate how cutaneous and rare melanomas can generate different proteomic signatures. Once identified, these biomarkers could eventually lead to new diagnostics and therapies.
"We are looking at what's happening in the tumor cells, as well as the types of immune cells inside tumors and the overall tumor microenvironment," Couts continued. "Illumina Protein Prep is helping us broaden our analyses to systemically investigate circulating proteins and the different factors that could be impacting the immune response."
More proteomics news from Illumina
In January, Illumina announced a pilot proteomics program with
In June, Illumina announced a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology. The move enhances Illumina's presence in the expanding proteomics market, advances the company's multiomics strategy, and reinforces the value of the NovaSeq X Series as an enabler of the next generation of multiomic applications.
Once the transaction closes, Illumina platforms will continue to support all NGS-based proteomics solutions. Illumina will also continue to support SomaLogic's currently offered array-based proteomics solutions. Until that time, Illumina and SomaLogic remain and will continue to operate as separate entities.
Early-access collaborators will be presenting at upcoming conferences, including the American Society of Human Genetics Annual Meeting in October, visit the event page, and the Human Proteome Organization World Congress in November.
To learn more, visit illumina.com/proteinprep.
Use of forward-looking statements
This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing and launching new products and services, including modifying and scaling manufacturing operations, and reliance on third-party suppliers for critical components; (ii) our ability to manufacture robust instrumentation and consumables; and (iii) the acceptance by customers of our newly launched products, which may or may not meet our and their expectations, and (iv) our ability to obtain any required regulatory clearances to close our acquisition of SomaLogic, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Contacts
Investors:
Illumina Investor Relations
858-291-6421
IR@illumina.com
Media:
Christine Douglass
PR@illumina.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-protein-prep-launches-to-drive-greater-proteomic-insights-for-improved-drug-discovery-and-development-302544648.html
SOURCE Illumina, Inc.
FAQ
What is Illumina's new Protein Prep technology and what can it measure?
How has Illumina Protein Prep improved diagnostic yield in the Genomics England study?
What is the significance of Illumina's acquisition of SomaLogic?
How many samples have been processed with Illumina Protein Prep during early access?
What is the UK Biobank proteomics pilot program with Illumina?
